Extended Data Table 1 Baseline demographics and disease characteristics in all dose-escalation cohorts (n = 83)

From: Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial

  1. a One patient received prior CTLA-4 therapy in addition to prior PD-(L)1 therapy.
Back to article page